Avita Medical Inc. (RCEL)
NASDAQ: RCELHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RCEL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $494.96M
- EPS (TTM)
- -$1.17
- Dividend yield
- None
- 52-week range
- 3.22 – 18.43
- Day range
- 15.51 – 16.26
- Volume / Avg
- 386.98K / 417.02K
- Beta
- —
- Shares outstanding
- 31.69M
52-week range
RCEL stock today
Avita Medical (RCEL) closed at $15.62 on Nov 20, down 2.31% (-$0.37), versus the S&P 500's 3.70% decline. At this level, RCEL sits near the top of its 52-week range of $3.22 to $18.43: 15.2% below the high, set on Nov 9, 2026 and 385.1% above the low. RCEL is up 352.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 312.1%.
Avita Medical has posted a net loss over the last twelve months (EPS of -$1.17), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Avita Medical
Company profileAVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Cary G. Vance
- Headquarters
- Valencia, CA
- Employees
- 226
- Website
- avitamedical.com
Financial highlights
Full financialsIn fiscal 2025, Avita Medical generated $71.6 million in revenue, up 11.5% from fiscal 2024, its 7th consecutive year of revenue growth. Avita Medical reported a net loss of $48.6 million, compared with a loss of $61.8 million a year earlier. Gross margin was 82.1% (down from 85.8%) and operating margin -59.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $71.61M | $64.25M | $50.14M | $34.42M | $29.23M |
| Growth | +11.45% | +28.14% | +45.68% | +17.75% | +104.95% |
| Net income | $-48.59M | $-61.84M | $-35.38M | $-26.66M | $-26.58M |
| EPS (diluted) | $-1.74 | $-2.39 | $-1.40 | $1.07 | $1.17 |
Analyst forecast
ForecastConsensus (3 analysts)
strong_buy
Avg. price target
$20.69+32.46%
- Strong buy 0
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.20 vs —
RCEL news
All RCEL news- AVITA Medical Reports Complete Cohealyx I Data in Full-Thickness Wounds Showing Earlier Graft Readiness and Six-Month Healing OutcomesGlobeNewswire
- AVITA Medical Consensus Price Target Increased by 48.78% to $20.74Nasdaq
- AVITA Medical to Host Investor Webinar BriefingGlobeNewswire
- AVITA Medical (RCEL) Q3 2026 Earnings Call TranscriptNasdaq
- AVITA Medical Announces National Medicare Physician Payment Framework and Simplified Billing Codes for RECELL Procedures in 2027GlobeNewswire
- AVITA Medical Consensus Price Target Increased 10.81% to $13.94Nasdaq
- AVITA Medical to Announce Third Quarter 2026 Financial ResultsGlobeNewswire
- Biotech Stocks At 52-Week Highs - HUM +11%, MRNA +14%, PBYI, ABBV, RCELNasdaqABBV, HUM, MRNA, PBYI
Avita Medical peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CARLCarlsmed Inc. | 17.42 | +1.16% | $477.38M | vs RCEL |
| ANGOAngioDynamics Inc. | 10.81 | +0.46% | $454.61M | vs RCEL |
| MDXGMiMedx Group Inc | 3.05 | -1.93% | $445.07M | vs RCEL |
| SENSSenseonics Holdings Inc. | 8.02 | -9.94% | $439.34M | vs RCEL |
| SGHTSight Sciences Inc. | 10.18 | -4.14% | $565.79M | vs RCEL |
| SIShoulder Innovations Inc. | 20.15 | -0.79% | $421.58M | vs RCEL |
| TCMDTactile Systems Technology Inc. | 25.60 | -1.50% | $573.48M | vs RCEL |
| MOBIMobia Medical Inc. | 11.85 | -0.08% | $394.50M | vs RCEL |
Indexes, lists and sector
Avita Medical stock FAQ
What is Avita Medical's stock price today?
RCEL last traded at $15.62 as of Nov 20, 4:00 PM EST, down 2.31% on the day. Prices are delayed at least 15 minutes.
Does Avita Medical pay a dividend?
No. Avita Medical does not currently pay a regular cash dividend.
Who is Avita Medical's CEO?
Mr. Cary G. Vance is the chief executive officer of Avita Medical Inc., which has about 226 employees.
Has RCEL ever split its stock?
Yes. The most recent RCEL stock split was a 1-for-5 split on Jun 30, 2020.
What is the RCEL 52-week high?
The 52-week high for RCEL is $18.43 and the 52-week low is $3.22. The stock is currently 15.2% below its high.